Better Science, Faster Answers: What Rare Disease Communities Need to Know About NAMs
You want faster cures. So why defend a system that keeps failing?
Rare disease communities are right about one thing: the system is too slow.
But where the conversation breaks down is this—many are criticizing change without fully understanding what’s broken in the first place.
There is growing backlash against the FDA’s move toward New Approach Methodologies (NAMs) and reduced reliance on animal testing. The reaction is emotional, urgent, and understandable.
But urgency without understanding doesn’t accelerate progress—it risks slowing it down.
The uncomfortable truth: most “promising” science never helps patients
Here’s what the data actually shows:
More than 90% of drugs that appear successful in animal studies never become approved human treatments (FDA, 2025: https://www.fda.gov/media/186092/download).
Let that sink in.
Even after entering clinical trials, only about 5–10% of therapies ever reach FDA approval.
This is not a minor inefficiency.
This is a systemic failure in predictability.
And for rare disease patients—this matters more than anywhere else.
Because you don’t have:
Time to waste
Capital to burn
Or large populations to absorb repeated failure
Billions spent. Years lost. And still no answers.
Developing a single drug can cost $1–2+ billion, with much of that tied to preclinical work and failed programs.
A significant portion of that cost comes from animal studies—especially long-term toxicology.
For example, in monoclonal antibody development, programs can involve 100+ non-human primates per drug (FDA announcement:
https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs).
And despite that scale?
Many of these therapies still fail in humans.
So the real question isn’t:
“Why change the system?”
It’s:
Why keep investing in a system that doesn’t predict human outcomes well?
Animal models aren’t the enemy—but they aren’t enough
Animal research has contributed to science. That’s not the debate.
The issue is predictability.
Species differences change how drugs behave
Rare genetic diseases are often poorly replicated in animals
Modern therapies (biologics, precision medicine) are highly human-specific
Yet instead of questioning these limitations, many default to defending them.
That’s not innovation.
That’s comfort.
Science has evolved. The model needs to catch up.
We are no longer limited to approximating human biology.
We can now study it directly.
Today’s toolkit includes:
iPSC-derived patient cell models (your biology, not a proxy)
Organoids that mimic real human organs
Organ-on-chip systems simulating human physiology
AI-driven toxicology models predicting safety earlier
Real-world human safety data from global populations
Phase 0 microdosing studies for early human insights
Programs like the NIH Tissue Chip initiative are actively advancing these tools using human biology, not animal approximation:
https://ncats.nih.gov/tissuechip
This isn’t experimental fringe science.
This is where the field is going—because it works better.
This isn’t about lowering standards—it’s about raising relevance
One of the biggest misconceptions is that FDA is “removing safety requirements.”
That’s simply not true.
The FDA is allowing for more relevant evidence, not less evidence.
Through its alternative methods framework, the agency is working to:
Reduce unnecessary animal use
Replace it where scientifically justified
Maintain strict safety standards
You can review that directly here:
https://www.fda.gov/science-research/advancing-alternative-methods-fda/implementing-alternative-methods
This is not deregulation.
It’s modernization.
Let’s talk about what no one wants to say out loud
Non-human primates used in research can live for decades.
Inducing disease and subjecting them to long-term testing raises real ethical questions—especially when the predictive value is limited.
You don’t have to ignore that to advocate for patients.
And you don’t have to choose between compassion and science.
But you do have to ask:
Are we holding onto outdated methods because they work—or because they’re familiar?
Advocacy is powerful. But it’s not enough.
Rare disease communities have driven incredible change.
Funding research. Building organizations. Pushing trials forward.
That matters.
But here’s the reality:
Advocacy does not guarantee a cure.
Science does.
And good science requires:
Better models
Better data
Better decision-making early in development
Not just more activity.
If you want better outcomes, you need better thinking
This is the part that’s uncomfortable.
Because it requires stepping back and asking:
Are we pushing for what feels right?
Or what actually works?
Defending a system with a 90% failure rate is not strategic.
It’s reactive.
The future of medicine is human-relevant
This shift toward NAMs is not anti-patient.
It is pro-patient efficiency.
Pro-science.
Pro-outcomes.
It’s about:
Reducing failure rates
Improving prediction
Accelerating timelines
Using resources more effectively
And yes—reducing unnecessary animal use where science supports it
The bottom line
The goal is not more trials.
The goal is not more noise.
The goal is:
Trials that actually work in humans.
And getting there requires something many people resist:
Change.